Can kidney size predict disease progression in ADPKD? new study investigates
NCT ID NCT06193616
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This observational study reviews medical records from 70 adults with advanced autosomal dominant polycystic kidney disease (ADPKD) who are already taking the drug octreotide LAR. Researchers want to see if baseline kidney volume and other factors can predict how quickly kidney function declines over time. The goal is to better understand the disease course, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- octreotide LAR
- What this could lead to
- If successful, this study could help doctors better predict which patients with advanced ADPKD will have faster kidney decline, potentially guiding treatment decisions.
- What could go wrong
- This is a small, retrospective, observational study—it cannot prove cause and effect. Results may not apply to all patients, and no new treatment is being tested.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ASST HPG23 - Unità di Nefrologia
Bergamo, BG, 24100, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.